Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 13/20 | 0.57 |
| ▸ | THRA | P10827 | 12/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CDC25A | P30304 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165596 | 0.93 | THRB (0.48) | THRBTHRACDC25ACDC25BHIF1A | |
| SCHEMBL3156536 | 0.89 | THRB (0.55) | THRBTHRAPTPN1CDC25ACDC25B | |
| SCHEMBL5137408 | 0.87 | THRB (0.42) | THRBTHRACDC25ACDC25BHIF1A | |
| SCHEMBL4199500 | 0.86 | THRB (0.41) | THRBTHRA | |
| SCHEMBL4199508 | 0.86 | THRB (0.40) | THRBTHRACDC25ACDC25BHIF1A | |
| SCHEMBL3153400 | 0.85 | THRB (0.54) | THRBTHRAPTPN1 | |
| SCHEMBL3161477 | 0.84 | THRB (0.61) | THRBTHRAPTPN1 | |
| SCHEMBL3147737 | 0.84 | THRB (0.74) | THRBTHRAPTPN1 | |
| SCHEMBL27713141 | 0.83 | THRB (0.39) | THRBTHRACDC25ACDC25BHIF1A | |
| SCHEMBL281846 | 0.82 | THRB (0.58) | THRBTHRAPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1891080-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1890768-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128056-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128055-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | PYGL, THRA, THOP1 | THRB 6/4885THRA 2/4885PTPN1 70/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | THRB 6/4885THRA 2/4885PTPN1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.